Evidence map›Paper›PMID 27048364›Full record

ArticleJournal of ovarian research2016

Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer.

Sebastian Lundgren, Jonna Berntsson, Björn Nodin, Patrick Micke, Karin Jirström

Open access · goldAbstract read
In one paragraph

Article in Journal of ovarian research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 118 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sebastian LundgrenDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University, SE-221 85, Lund, Sweden. sebastian.lundgren@med.lu.se.
Jonna BerntssonDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University, SE-221 85, Lund, Sweden.
Björn NodinDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University, SE-221 85, Lund, Sweden.
Patrick MickeDepartment of Immunology, Genetics and Pathology, Uppsala University, SE-751 85, Uppsala, Sweden.
Karin JirströmDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University, SE-221 85, Lund, Sweden.
Lund University · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe critical role of the immune system in controlling cancer progression has become evident and immune modulatory therapy is now approved for clinical use. However, while the majority of studies on the inflammatory tumour microenvironment have focused on the cellular immune response, in particular the prognostic and predictive role of various T cell infiltrates, the role of the humoral immune response in this context has long been overlooked. This study aimed to investigate the clinicopathological correlates and prognostic impact of B cell and plasma cell infiltration in epithelial ovarian cancer (EOC).

methodsImmunohistochemical expression of immunoglobulin kappa C (IGKC), CD20 and CD138 was analysed in tissue microarrays with tumours from 154 incident cases of EOC from two pooled prospective population-based cohorts. Subsets of corresponding benign-appearing fallopian tubes (n = 38) and omental metastases (n = 33) were also analysed. Kaplan-Meier analysis and Cox regression analysis were used to determine the impact of immune-cell specific IGKC, CD20 and CD138 expression on overall survival and ovarian cancer-specific survival.

resultsHigh IGKC expression correlated significantly with expression of CD20 (p = 0.001) and CD138 (p = 0.035). Expression of IGKC as well as CD138 was significantly higher in primary tumours than in fallopian tubes (p = 0.004 and p = 0.001, respectively). High CD20 and CD138 expression correlated significantly with high tumour grade (p = 0.032 and p = 0.030, respectively). CD20 and IGKC expression was not prognostic but univariable Cox regression analysis revealed high CD138 expression to correlate with a significantly reduced overall survival (HR = 2.20; 95 % CI 1.34-3.55; p-0.001) as well as ovarian cancer-specific survival (HR = 1.95; 95 % CI 1.28-2.98; p = 0.002). The prognostic impact was independent of established clinical parameters (age, grade, clinical stage) as shown in multivariable analysis (HR = 2.28; 95 % CI 1.39-3.75; p = 0.001).

conclusionsIn conclusion, our results demonstrate that plasma cell infiltration in epithelial ovarian cancer has a significant impact on tumour progression and prognosis. The important role of the humoral immune system merits further study and may be harnessed as immune modulatory strategies in cancer therapy.

Indexed as

AdultAntigens, CD20B-LymphocytesCarcinoma, Ovarian EpithelialFallopian TubesFemaleHumansImmunoglobulin kappa-ChainsKaplan-Meier EstimateMultivariate AnalysisNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisProportional Hazards ModelsProspective StudiesSyndecan-1Antigens, CD20Immunoglobulin kappa-ChainsSDC1 protein, humanSyndecan-1CD138CD20Immunoglobulin kappa cOvarian cancerPrognosisSyndecan-1

Identifiers

PMID27048364
PMCPMC4822228
OpenAlexW2328673944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.